MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Lysosomal disorders"

  • 2025 International Congress

    Oligodendrocyte-specific mRNA therapy with lipid nanoparticles

    M. Sawamura, K. Tachikawa, R. Hikawa, H. Yamakado, R. Takahashi, S. Matsuzawa (San Diego, USA)

    Objective: To develop lipid nanoparticles with high efficiency and specificity to introduce mRNA into oligodendrocytes. To denmonstrate the potential therapy of Krabbe disease as one…
  • 2025 International Congress

    G-Can, the GBA1 Canada Initiative

    L. Chebon, P. Halder, E. Fon, T. Durcan, M. Parent, N. Dupre, M. Sharp, R. Postuma, G. Armstrong, A. Milnerwood, A. Dagher, J. Raamsdonk, J. Trempe, T. Goldsmith, X. Chen, N. Aprahamian, Z. You, M. Nicoleau, E. Deneault, A. Bayne, C. Laflamme, P. Mcpherson, M. Pandolfo, G. Rouleau, Z. Gan-Or (Québec, Canada)

    Objective: G-Can, the GBA1 Canada Initiative, is an open-science platform which aims to advance GBA1 research and develop treatments for GBA1 mutation-related Parkinson's disease (PD).…
  • 2025 International Congress

    Investigating the cellular consequences of the G2385R LRRK2 variant

    P. Lewis, S. Herbst (London, United Kingdom)

    Objective: The objective of this study is to characterise the biochemical and cellular impact of the G2385R coding variant in LRRK2, a risk variant for…
  • 2025 International Congress

    CSM-101 is a Small Molecule Agonist of TRPML1 for Parkinson’s-Related Disorders

    L. Murphy, J. Fortanet, D. Baird, T. Lehmberg, K. Skerry, M. Broadus (Boston, USA)

    Objective: (i) To develop a brain-penetrant small molecule agonist for the lysosomal TRPML1 channel and, (ii) Perform preclinical studies supporting development in Parkinson’s-related disorders. Background:…
  • 2025 International Congress

    VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease

    M. Facheris, D. Ysselstein, J. van Dervalk, E. Thijssen, L. Pagan, G. Valstar, C. Schotborgh, P. Kremer, M. Hagey, J. Cederbaum, J. Sullivan, K. Hunt, O. Siddiqui (Chicago, USA)

    Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…
  • 2025 International Congress

    The sphingolipid Lyso-Gb3, a biomarker for the lysosomal storage disorder Fabry Disease, is significantly elevated in blood from patients with Parkinson’s Disease

    C. Beetz, C. Cozma, M. Iurascu, S. Fischer, S. Oppermann, K. Kandaswamy, P. Bauer (Rostock, Germany)

    Objective: To better understand lysosomal dysfunction in Parkinson’s Disease. Background: Lysosomal dysfunction and α-synuclein accumulation play central roles in Parkinson’s Disease. They are interconnected by…
  • 2025 International Congress

    The Role of Autophagy Lysosomal and Ubiquitin Proteasomal System in the Pathophysiology of Parkinson’s disease.

    B. Adebisi (Akure, Nigeria)

    Objective: The research how to better understand the molecular mechanism initiating the etiology of Parkinson's disease in order to appropriate the precise diagnosis and therapeutic…
  • 2025 International Congress

    GCase and Ganglioside GM1 Interaction in Parkinson’s Disease

    F. Fierli, G. Uras, S. Lucas Del-Pozo, S. Koletsi, V. Lentini, A. Schapira (London, United Kingdom)

    Objective: The project aims to further understand the role of the ganglioside GM1 in the relationship between GBA1 mutations and higher α-synuclein levels. Background: Among…
  • 2025 International Congress

    Modeling Inflammation in GBA-Associated Parkinson’s Disease: Insights into Disease Mechanisms

    V. Lentini, G. Uras, S. Lucas, D. Moreno-Martinez, A. Manca, F. Fierli, S. Koletsi, A. Pantaleo, D. Hughes (Sassari, Italy)

    Objective: This investigation centers on the role of inflammation in GBA-associated Parkinson’s disease (PD), a neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons,…
  • 2025 International Congress

    Neuroprotective Effects of ATP6V0C Overexpression in PFF Model Mice

    Y. Wang, Y. Xia, L. Kou, T. Wang (wuhan, China)

    Objective: Elucidating the role of lysosomal dysfunction due to altered stability and expression levels of V-type proton subunit ATP6V0C in the degradation and propagation of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 10
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley